Oncolytics Biotech Inc. is a biotech company headquartered in San Diego, California, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| ONCY | ONCOLYTICS BIOTECH INC | 2026-11-02 09:56:08 | 0.42 | -0.01 | -2.75 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ONCY | 0001129928 | ONCOLYTICS BIOTECH INC | US68237V1035 | — | 980541667 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | NV | SUITE 325, 4350 EXECUTIVE DRIVE | SAN DIEGO | CA | 92121 | UNITED STATES | US | 4036707377 | SUITE 325, 4350 EXECUTIVE DRIVE, SAN DIEGO, CA, 92121 | SUITE 325, 4350 EXECUTIVE DRIVE, SAN DIEGO, CA, 92121 | — | — | 1998 | — | — | http://www.oncolyticsbiotech.com | 72,100,000 | 124,637,521 | 127,510,505 | Oncolytics Biotech Inc. is a biotech company headquartered in San Diego, California, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. | 2026-10-30 05:56:57 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 72,100,000 | 72,100,000 | 100 | 116,128,162 | 116,128,162 | 100 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Thomas C. Heineman | Chief Medical Officer | 2025 | 550,971 | 0 | 0 | 110,500 | 14,000 | 1,197,342 |
| Wayne Pisano | CEO | 2025 | 110,000 | 0 | 124,419 | 50,000 | 40,000 | 433,141 |
| Jared Kelly | Chief Executive Officer | 2025 | 318,093 | 0 | 0 | 0 | 9,583 | 2,108,512 |
| Kirk Look | Chief Financial Officer | 2025 | 460,978 | 0 | 0 | 90,500 | 23,705 | 1,122,229 |
| Thomas C. Heineman | Chief Medical Officer | 2024 | 521,027 | 0 | 167,818 | 0 | 13,800 | 790,842 |
| Fiscal Year | 2025 |
|---|---|
| Revenue | — |
| Cost Of Revenue | — |
| Gross Profit | 0 |
| Research And Development Expenses | 13,314,000 |
| General And Administrative Expenses | 15,411,000 |
| Operating Expenses | 28,725,000 |
| Operating Income | -28,725,000 |
| Net Income | -28,759,000 |
| Earnings Per Share Basic | -0.3 |
| Earnings Per Share Diluted | -0.3 |
| Weighted Average Shares Outstanding Basic | 95,857,147 |
| Weighted Average Shares Outstanding Diluted | 95,857,147 |
| Fiscal Year | 2025 |
|---|---|
| Cash And Cash Equivalents | 5,202,000 |
| Marketable Securities Current | — |
| Accounts Receivable | — |
| Inventories | — |
| Non Trade Receivables | 573,000 |
| Other Assets Current | 1,069,000 |
| Total Assets Current | 6,844,000 |
| Marketable Securities Non Current | — |
| Property Plant And Equipment | 228,000 |
| Other Assets Non Current | — |
| Total Assets Non Current | 738,000 |
| Total Assets | 7,582,000 |
| Accounts Payable | 3,504,000 |
| Deferred Revenue | — |
| Short Term Debt | — |
| Other Liabilities Current | 0 |
| Total Liabilities Current | 6,101,000 |
| Long Term Debt | — |
| Other Liabilities Non Current | — |
| Total Liabilities Non Current | 5,280,000 |
| Total Liabilities | 11,381,000 |
| Common Stock | 0 |
| Retained Earnings | -429,495,000 |
| Accumulated Other Comprehensive Income | 6,225,000 |
| Total Shareholders Equity | -3,799,000 |
| Fiscal Year | 2025 |
|---|---|
| Depreciation And Amortization | 70,000 |
| Share Based Compensation Expense | 3,104,000 |
| Other Non Cash Income Expense | — |
| Change In Accounts Receivable | — |
| Change In Inventories | — |
| Change In Non Trade Receivables | -3,000 |
| Change In Other Assets | — |
| Change In Accounts Payable | 2,932,000 |
| Change In Other Liabilities | -360,000 |
| Cash From Operating Activities | -20,112,000 |
| Purchases Of Marketable Securities | — |
| Sales Of Marketable Securities | — |
| Acquisition Of Property Plant And Equipment | 6,000 |
| Acquisition Of Business | — |
| Other Investing Activities | — |
| Cash From Investing Activities | -6,000 |
| Tax Withholding For Share Based Compensation | — |
| Payments Of Dividends | — |
| Issuance Of Common Stock | 32,000 |
| Repurchase Of Common Stock | — |
| Issuance Of Long Term Debt | — |
| Repayment Of Long Term Debt | — |
| Other Financing Activities | -27,000 |
| Cash From Financing Activities | 14,120,000 |
| Change In Cash | -5,877,000 |
| Cash At End Of Period | 5,202,000 |
| Income Taxes Paid | 67,000 |
| Interest Paid | — |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| McAdory John Bearden | Chief Operating Officer | 2026-06-01 | 145,000 | A | 145,000 |
| Glover Stephen C. | Director | 2026-06-01 | 96,000 | A | 96,000 |
| Brown Deborah Margaret | Director | 2026-06-01 | 30,000 | A | 30,000 |
| Pisano Wayne | Director | 2026-06-01 | 30,000 | A | 30,000 |
| Holtham Angela | Director | 2026-06-01 | 30,000 | A | 30,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Creative Planning | 2026-09-30 | 8,687 | 13,000 | 0.6682 |
| TRUIST FINANCIAL CORP | 2026-09-30 | 13,364 | 20,000 | 0.6682 |
| INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | 2026-09-30 | 129,208 | 462,008 | 0.2797 |
| EVOLUTION WEALTH MANAGEMENT INC. | 2026-09-30 | 70 | 105 | 0.6667 |
| D.A. DAVIDSON & CO. | 2026-09-30 | 9,906 | 14,825 | 0.6682 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Invesco Exchange-Traded Fund Trust II | 2026-08-31 | Invesco NASDAQ Future Gen 200 ETF | QQQS | 107,519 | 90,122.43 | 0.4002 |
| VICTORY PORTFOLIOS III | 2026-07-31 | Victory Extended Market Index Fund | USMIX | 13,506 | 10,174.07 | 0.0013 |
| FIDELITY CONCORD STREET TRUST | 2026-05-31 | Fidelity Nasdaq Composite Index Fund | FNCMX | 66,939 | 69,616.56 | 0.0002 |
| FIDELITY CONCORD STREET TRUST | 2025-11-30 | Fidelity Nasdaq Composite Index Fund | FNCMX | 66,939 | 66,724.8 | 0.0003 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Nasdaq Composite Index Fund | FNCMX | 66,939 | 69,616.56 | 0.0003 |